Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Alnylam Pharmaceuticals, with 16 buy, two strong-buy and five hold ratings among 23 firms. The average 12-month price target is $367.20, although several firms recently lowered their targets.
• Alnylam shares opened at $244.32, near the lower end of their 52-week range of $197.81 to $495.55, while institutional investors and hedge funds own 92.97% of the stock.
• The company exceeded quarterly EPS expectations, reporting $1.84 versus the $1.63 consensus estimate, while revenue rose 66.9% year over year to $1.29 billion but fell slightly short of forecasts.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-three research firms that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $367.20.

ALNY has been the subject of several recent analyst reports. Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $400.00 to $300.00 and set an "equal weight" rating for the company in a report on Friday, July 31st. Citigroup reduced their price target on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a "buy" rating for the company in a report on Monday, August 3rd. Royal Bank Of Canada decreased their price objective on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an "outperform" rating for the company in a report on Friday, July 31st. Wells Fargo & Company lowered their price target on shares of Alnylam Pharmaceuticals from $316.00 to $256.00 and set an "equal weight" rating on the stock in a research note on Friday, August 14th. Finally, Jefferies Financial Group upped their price objective on Alnylam Pharmaceuticals from $230.00 to $260.00 and gave the stock a "hold" rating in a research note on Tuesday, September 8th.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. MV Capital Management Inc. acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $25,000. Manchester Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 600.0% in the 4th quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 72 shares during the last quarter. Leonteq Securities AG acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth $42,000. Titan Wealth CI Ltd acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth about $42,000. Finally, SHP Wealth Management bought a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $43,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Up 2.0%

Shares of NASDAQ:ALNY opened at $244.32 on Tuesday. The company has a 50 day moving average price of $246.41 and a two-hundred day moving average price of $285.10. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The company has a market capitalization of $32.69 billion, a PE ratio of 45.41 and a beta of 0.31. Alnylam Pharmaceuticals has a 52 week low of $197.81 and a 52 week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm's revenue was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.51) EPS. Analysts forecast that Alnylam Pharmaceuticals will post 6.71 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi) technology. RNAi therapies are designed to silence specific genes involved in disease, offering a way to target conditions that may be difficult to treat with conventional drug approaches. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam's commercial products include Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and Amvuttra (vutrisiran).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.